Skip to main content
Glama

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

TDQS

A4.8/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

The description adds substantial behavior beyond the readOnly/openWorld/idempotent annotations: unresolved identifiers are listed under `unresolved` rather than omitted, ambiguous names return `figi_candidates` without asserting, and GLEIF/OpenFIGI failures degrade gracefully while EDGAR identifiers still return. It also explains source labelling and internal cascading lookups.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness5/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is long but information-dense, and its structure helps: query examples and the core 'resolve name to ID' statement come first, followed by typed details and edge-case behavior. Every sentence contributes behavior, parameter guidance, or caveats; there is no filler.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

With no output schema, the description carries the burden of explaining return behavior, and it does so: it lists what is returned for company and drug types, names fields like `figi_candidates` and `unresolved`, and covers fallback behavior. An agent has enough context to select and call this tool correctly.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Even though the schema already covers both parameters, the description adds critical semantics: accepted inputs (ticker, CIK, ISIN, company name; brand or generic drug name) and a specific warning to pass only the entity name, never the full noun phrase, with a bond example. This is exactly the kind of guidance an agent needs to invoke `value` correctly.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description states a specific action — 'resolve a user-spoken NAME to the canonical/official identifiers other tools require as input' — and supports it with concrete query examples ('ticker', 'CIK', 'LEI', 'RxCUI'). It also distinguishes the tool's role by noting it is the first stop when a name but no ID is available, which differentiates it from identifier-consuming siblings like entity_profile.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

It gives an explicit trigger: 'Use FIRST whenever you have a name but need an ID.' It also clarifies that the tool replaces 2-3 manual lookups, implying a primary lookup role. It does not name sibling tools or state when not to use it, so it falls just short of full when/when-not guidance.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.9/5.0
Disambiguation3/5

Several tool groups (ask_pipeworx/ask_pipeworx_grounded/deep_research, conditions/disease_names, polymarket_* family) have overlapping purposes, requiring careful reading of descriptions to differentiate. While many tools are conceptually distinct, the similarity within domains could lead to agent misselection.

Naming Consistency3/5

Naming is mostly snake_case but patterns vary: verb_noun (ask_pipeworx), noun_noun (entity_profile), single verb (forget, recall), and some adjectives (recent_changes). No consistent structure across the set, though individual names are descriptive.

Tool Count2/5

With 40 tools, the server is overly large for typical coherence. The tool count exceeds the 15–25 range deemed borderline, making it hard for agents to navigate and select efficiently.

Completeness4/5

The surface covers medical coding (ICD, LOINC, UCUM, drugs, procedures), financial data, prediction markets, memory, subscriptions, and meta-tools. Missing but minor elements (e.g., CPT codes) do not significantly hinder common workflows.